Difference between revisions of "Timeline of diphtheria"

From Timelines
Jump to: navigation, search
Line 19: Line 19:
 
| 1884 || Scientific development || German bacteriologist [[wikipedia:Friedrich Loeffler|Friedrich Loeffler]] first grows diphtheria bacterium ''[[wikipedia:Corynebacterium diphtheriae|corynebacterium diphtheriae]]'' in pure culture.<ref name="Diphtheria in Europe">{{cite web|last1=KWANTES|first1=W.|title=Diphtheria in Europe|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2129475/pdf/jhyg00015-0039.pdf|website=nih.gov|accessdate=8 May 2017}}</ref> || [[wikipedia:Germany|Germany]]
 
| 1884 || Scientific development || German bacteriologist [[wikipedia:Friedrich Loeffler|Friedrich Loeffler]] first grows diphtheria bacterium ''[[wikipedia:Corynebacterium diphtheriae|corynebacterium diphtheriae]]'' in pure culture.<ref name="Diphtheria in Europe">{{cite web|last1=KWANTES|first1=W.|title=Diphtheria in Europe|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2129475/pdf/jhyg00015-0039.pdf|website=nih.gov|accessdate=8 May 2017}}</ref> || [[wikipedia:Germany|Germany]]
 
|-
 
|-
| 1890 || Medical development || German physiologist [[wikipedia:Emil von Behring|Emil von Behring]] develops the first effective therapeutic serum against diphtheria. In 1901 Von Bering would be awarded the first [[Nobel Prize in Physiology or Medicine]] for this work.<ref name="Emil von Behring: The Founder of Serum Therapy">{{cite web|title=Emil von Behring: The Founder of Serum Therapy|url=https://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-article.html|website=nobelprize.org|accessdate=9 May 2017}}</ref><ref name="Vaccine Timeline"/> ||  
+
| 1890 || Medical development || German physiologist [[wikipedia:Emil von Behring|Emil von Behring]] develops the first effective therapeutic serum against diphtheria. In 1901 Von Bering would be awarded the first [[wikipedia:Nobel Prize in Physiology or Medicine|Nobel Prize in Physiology or Medicine]] for this work.<ref name="Emil von Behring: The Founder of Serum Therapy">{{cite web|title=Emil von Behring: The Founder of Serum Therapy|url=https://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-article.html|website=nobelprize.org|accessdate=9 May 2017}}</ref><ref name="Vaccine Timeline"/> ||  
 
|-
 
|-
 
| 1921 || Report || 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.<ref name="Diphtheria: The Plague Among Children">{{cite web|title=Diphtheria: The Plague Among Children|url=https://www.historyofvaccines.org/timeline?timeline_categories[]=50|website=historyofvaccines.org|accessdate=8 May 2017}}</ref>  || [[wikipedia:United States|United States]]
 
| 1921 || Report || 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.<ref name="Diphtheria: The Plague Among Children">{{cite web|title=Diphtheria: The Plague Among Children|url=https://www.historyofvaccines.org/timeline?timeline_categories[]=50|website=historyofvaccines.org|accessdate=8 May 2017}}</ref>  || [[wikipedia:United States|United States]]

Revision as of 11:13, 9 May 2017

Year/period Key developments
19th century Diphtheria infection grows significantly late in the century to become one of the major causes of death, fuelled by the industrial revolution and increasingly crowded urban centers.[1]

Full timeline

Year/period Type of event Event Present time geographical location
5th century BC Scientific development Diphtheria is first described by Greek physician Hippocrates.[2] Greece
1600s Scientific development Medical reports of a "deadly" strangulation disease first appear early in the century, and emerges as a greater threat with the growth.[1]
1826 Scientific development French physician Pierre Bretonneau gives diphtheria its official name diphtérite, derived from the Greek word for "leather" or "hide", which describes the pseudomembrane in the throat of the victims.[1][3]
1884 Scientific development German bacteriologist Friedrich Loeffler first grows diphtheria bacterium corynebacterium diphtheriae in pure culture.[4] Germany
1890 Medical development German physiologist Emil von Behring develops the first effective therapeutic serum against diphtheria. In 1901 Von Bering would be awarded the first Nobel Prize in Physiology or Medicine for this work.[5][6]
1921 Report 206,000 cases of diphtheria and 15,520 deaths are recorded in the United States.[7] United States
1923 Medical development Diphtheria toxoid is licensed; prepared from inactivated bacterial toxin that has lost its toxicity but retains its antitoxin producing properties.[6]
1924 Scientific development French biologist Gaston Ramon, working at Pasteur Institute, discoveres diphtheria and tetanus toxoid, then referred to as anatoxins.[8] France
1947 Medical development Combination diphtheria and tetanus toxoids for pediatric use is first licensed in the United States.[6] United States
1953 Medical development Tetanus and diphtheria toxoids (adult formulation) are first licensed in the United States, after the concentration of diphtheria toxoid is reduced.[6] United States
1974 Epidemic Diphtheria epidemic breaks out in Lisbon. 500 persons are involved, and about 40 deaths are recorded.[4] Portugal
1982 Epidemic 5 deaths are recorded in Germany during a diphtheria outbreak.[4] Germany
1996 Medical development Lederle Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Acel-Imune, for use as the first through fifth doses in the series.[6]
1997 Medical development British pharmaceutical company SmithKline Beecham licenses Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for the first four doses of the series.[6]
1998 Medical development North American Vaccine Inc licenses Certiva (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed), for boosting immunization of infants and children.[6]
1999 Medical development Connaught Laboratories licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Tripedia.[6]
2002 Medical development British pharmaceutical GlaxoSmithKline licenses Pediarix, a vaccine combining diphtheria, tetanus, acellular pertussis, inactivated polio, and hepatitis B antigens.[6]
2002 Medical development Aventis Pasteur licenses diphtheria and tetanus toxoids and acellular pertussis vaccine Daptacel.[6]
2004 Medical development Aventis Pasteur licenses vaccine Decavac, indicated for active immunization against tetanus and diphtheria.[6][9]
2005 Medical development Sanofi Pasteur licenses Menactra, the first meningococcal polysaccharide (Serogroups A, C, Y and W-135) diphtheria toxoid conjugate vaccine. This would be the first immunogenic meningococcal vaccine indicated for children younger than 2 years of age.[6]
2007 Report 4,190 cases of diphtheria are reported globally.[7]
2011 Medical development United States Food and Drug Administration approves Boostrix (developed by GlaxoSmithKline) to prevent tetanus, diphtheria, and pertussis in older people.[6] United States

See also

  1. 1.0 1.1 1.2 "The strangler". museumofhealthcare.ca. Retrieved 9 May 2017. 
  2. "Diphtheria". medscape.com. Retrieved 8 May 2017. 
  3. "Pierre Bretonneau". historyofvaccines.org. Retrieved 9 May 2017. 
  4. 4.0 4.1 4.2 KWANTES, W. "Diphtheria in Europe" (PDF). nih.gov. Retrieved 8 May 2017. 
  5. "Emil von Behring: The Founder of Serum Therapy". nobelprize.org. Retrieved 9 May 2017. 
  6. 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 "Vaccine Timeline". immunize.org. Retrieved 8 May 2017. 
  7. 7.0 7.1 "Diphtheria: The Plague Among Children". historyofvaccines.org. Retrieved 8 May 2017. 
  8. Medical Sciences - Volume I (B.P. Mansourian, S.M. Mahfouz, A. Wojtezak ed.). Retrieved 9 May 2017. 
  9. "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). vaccineshoppe.com. Retrieved 8 May 2017.